ArticleMethods in molecular biology (Clifton, N.J.)2026
FLEXMAP 3D Immunoproteomics: A Protocol to Characterize General Human Antibody Profiles Against Pathogens.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoproteomics allows the detection and characterization of multiple types of analytes (such as antigens and antibodies) from different sources of body fluids and tissue/cell lysates in healthy and diseased subjects. FLEXMAP 3D is a recent platform, which applies immunoproteomics as a main approach. It was previously used to profile and detect various types of analytes in a timely manner with high levels of accuracy, sensitivity, and specificity. In this chapter, a simplified protocol is stated of how we can characterize general human antibody profiles against pathogens using FLEXMAP 3D. In this experiment, we have looked for antibody response against 6 different bacterial/fungal supernatants in 16 patients' plasma (comparing 8 type 2 diabetes patients with 8 healthy people).
Indexed as
Identifiers
41085631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.